Edition:
United States

Corvus Pharmaceuticals Inc (CRVS.OQ)

CRVS.OQ on NASDAQ Stock Exchange Global Market

9.30USD
15 Dec 2017
Change (% chg)

$-0.94 (-9.18%)
Prev Close
$10.24
Open
$10.10
Day's High
$10.10
Day's Low
$9.20
Volume
441,522
Avg. Vol
23,563
52-wk High
$22.01
52-wk Low
$8.27

Chart for

About

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-onc... (more)

Overall

Beta: --
Market Cap(Mil.): $195.68
Shares Outstanding(Mil.): 21.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Corvus Pharmaceuticals reports third quarter 2017 financial results

* Corvus Pharmaceuticals reports third quarter 2017 financial results and clinical program update

Nov 02 2017

BRIEF-Corvus Pharmaceuticals entered into a sales agreement with Cowen and Co LLC‍​

* Corvus Pharmaceuticals - On September 20, 2017, Corvus Pharmaceuticals, Inc entered into a sales agreement with Cowen and Company, LLC‍​

Sep 20 2017

BRIEF-Corvus Pharmaceuticals qtrly ‍net loss per share $0.73​

* Corvus Pharmaceuticals reports second quarter 2017 financial results and provides business update

Aug 03 2017

Earnings vs. Estimates